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AbstrACt
Objectives Inhaled corticosteroids (ICS) reduce 
exacerbation rates and the decline in lung function in 
people with chronic obstructive pulmonary disease (COPD). 
There is evidence that smoking causes ‘steroid resistance’ 
and thus reduces the effect of ICS. This systematic review 
aimed to investigate the effect of smoking on efficacy of 
ICS in COPD in terms of lung function and exacerbation 
rates.
Design Systematic review.
Data sources An electronic database search of PubMed, 
Ovid MEDLINE, Ovid Embase and Cochrane Library 
(January 2000 to January 2020).
Eligibility criteria Fully published randomised controlled 
trials (RCTs), in the English language, evaluating the use 
of ICS in COPD adults that stratified the participants by 
smoking status. Trials that included participants with 
asthma, lung cancer and pneumonia were excluded. The 
primary outcome measures were changes in lung function 
and yearly exacerbation rates.
Data extraction and synthesis Two independent 
reviewers extracted data and assessed risk of bias using 
the Cochrane Collaboration’s tool.
results Seven studies were identified. Four trials (17 892 
participants) recorded change in forced expiratory volume 
in one second (FEV
1) from baseline to up to 30 months 
after starting treatment. Heavier smokers (>36 pack years) 
using ICS had a greater decline in FEV1 that ranged from 
−22 mL to −75 mL in comparison to lighter smokers. 
Smokers using ICS had mixed results in FEV1 change: 
−8 mL to +77 mL in comparison to ex- smokers. Four 
trials (21 270 participants) recorded difference in COPD 
exacerbation rates at 52 weeks. The rate ratios favoured 
more exacerbations in ICS users who were current or 
heavier smokers than those who were ex- smokers or 
lighter smokers (0.81 to 0.99 vs 0.92 to 1.29).
Conclusions In COPD, heavier or current smokers do not 
gain the same benefit from ICS use on lung function and 
exacerbation rates as lighter or ex- smokers do, however 
effects may not be clinically important.
PrOsPErO registration number CRD42019121833
IntrODuCtIOn
Cigarette smoking is a causative factor in 
chronic obstructive pulmonary disease 
(COPD) and it is estimated that worldwide, 
around 80% of people with COPD are current 
or ex- smokers.1 2 In addition to contributing 
to an increased rate of lung function decline, 
recently it has been postulated that smoking 
may cause resistance to some drug treat-
ments; most notably inhaled corticosteroids 
(ICS).3 4 Asthmatic patients who smoke often 
require higher doses of ICS for control of 
their disease.5 The mechanism for this resis-
tance has yet to be fully established.
ICS reduce exacerbation rates and possibly 
reduce the decline in lung function, as 
measured by forced expiratory volume in one 
second (FEV1), in comparison to placebo for 
people with COPD.6 7 As a result, ICS have 
been a mainstay of COPD treatment for some 
time. However, there has been some contro-
versy around the use of ICS; most notably that 
not all people with COPD benefit from their 
use,8 9 and the vast array of adverse effects 
that long- term use of these medicines cause. 
It is well- established that ICS are highly effec-
tive anti- inflammatory agents in asthma yet 
efficacy in COPD, even at high doses, remains 
debated. The reasons for this are likely to be 
complex and multifactorial, however resis-
tance to ICS due to smoking is one possible 
factor.
strengths and limitations of this study
 ► Patient- orientated outcomes were recorded at up to 
30 months, making results applicable to practice.
 ► Two of the included trials are post hoc analyses of 
the same original trial. The original trial recruited 
few participants making it unreliable.
 ► The trials were heterogeneous in terms of classifi-
cation of smoking status and outcome measures, 
making direct comparison difficult and unable to 
undertake meta- analysis.
 ► There was limited reporting of statistical analysis in 
the original trials and difficulty extracting all relevant 
data, making the reliability of results unknown.
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One of the mechanisms by which ICS suppress inflam-
mation in COPD is by acting on histone deacetylase-2 
(HDAC-2) to inhibit the release of inflammatory medi-
ators such as tumour necrosis factor alpha and inter-
leukin-8 that activate inflammatory cells.10 Several 
animal models and in vitro studies have shown that 
cigarette smoke reduces the activity and expression 
of HDAC-2 in alveolar macrophages by imposing an 
oxidative stress in the lungs.11 Cigarette smoke contains 
several reactive oxygen species (ROS) and other 
noxious particles which generate ROS. Cigarette smoke 
also contains nitric oxide which combines with ROS to 
generate peroxynitrite. In mice exposed to cigarette 
smoke, peroxynitrite causes the nitration of HDAC-2, 
which consequently leads to a loss in HDAC-2 func-
tion.11 This reduction in levels and function of HDAC-2 
prevent ICS from exerting the anti- inflammatory effect, 
thereby causing steroid resistance.12
It is not yet clear if smoking cessation reduces steroid 
resistance; it was noted that airway mucosal inflammation 
may persist even after smoking cessation.13 However there 
are many other benefits that smoking cessation brings 
on disease control in COPD; including reduced disease 
progression and reduced exacerbation rates.3 One small 
study found that there may even be a small element of 
steroid resistance caused by direct interaction of envi-
ronmental tobacco smoke and aerosolised corticosteroid 
particles; which may alter drug deposition in the lungs 
and a subsequent decline in steroid efficacy.14
While there remains cellular observation of the resis-
tance to ICS in smokers with COPD, as yet the clinical 
significance on patient outcomes, such as lung function 
and exacerbation rates, is still to be fully investigated; no 
systematic review of the evidence has been published.
MEthODs
This systematic review was registered with PROSPERO 
(https://www. crd. york. ac. uk/ prospero/). In addition, 
the full search strategy can be found in the online supple-
mentary information.
Literature search
This systematic review was conducted by an electronic 
database search in PubMed (January 2000 to January 
2020), Ovid MEDLINE (January 2000 to January 
2020), Ovid Embase (January 2000 to January 2020) 
and Cochrane Library (January 2000 to January 2020). 
A structured search strategy including free text and 
Medical Subject Headings terms related to randomised 
controlled trial, COPD, smoking and inhaled corticoste-
roids (budesonide, fluticasone, ciclesonide, mometasone 
and beclometasone) was used to retrieve literature for 
this systematic review. The reference lists of the retrieved 
papers were also searched to identify further relevant 
studies.
Inclusion criteria
Fully published randomised controlled trials (RCTs) 
evaluating the use of ICS in COPD adults that strati-
fied the participants by smoking status were included. 
Review articles, abstracts, papers which are not fully 
published or published in languages other than English 
were not included. Retrieved trials that included COPD 
patients with asthma, lung cancer and pneumonia were 
also excluded. Trials that did not stratify participants by 
smoking status or smoking pack- years were also excluded.
Data extraction
Information about the study characteristics which include 
the study design and length, settings, participants’ age, 
diagnostic criteria for COPD, severity of COPD, ICS 
type, dose and frequency, duration of the intervention 
and frequency of follow- up were extracted. An estimated 
effect of ICS on the outcomes reported was calculated for 
each participant subgroup. The outcome measures were: 
difference in mean change of lung function between 
subgroups, as measured by FEV1, and rate ratio of yearly 
exacerbations.
Quality assessment
Risk of bias and quality assessment of all included 
studies was assessed using the Cochrane Collaboration 
tool for assessing risk. Where disagreement occurred, 
this was discussed and a consensus reached. Informa-
tion extraction was completed by one researcher and 
confirmed by a second.
PAtIEnt AnD PubLIC InvOLvEMEnt
No patient involved.
rEsuLts
Seven RCTs were identified for inclusion in this systematic 
review (figure 1). Two further studies were identified as 
being potentially suitable: Bafadhel et al and Hoonhorst 
et al.15 16 The data in Bafadhel et al was not presented in 
a way that could be extracted for this systematic review 
and it’s results are discussed separately. On closer inspec-
tion the analysis in Hoonhorst et al was a post hoc analysis 
of the Groningen Leiden Universities Corticosteroids in 
Obstructive Lung Disease (GLUCOLD) trial, the same as 
the study by Snoeck- Stroband et al.17 18 It was not clear if 
the same patient group was analysed in both studies, and 
as the Hoonhorst study was methodologically flawed in 
terms of powering of the study, it has not been included. 
Additionally, Hinds et al and Pascoe et al reported 
secondary analysis of the FLAME and IMPACT studies 
respectively;19 20 it is uncertain if these were prespecified 
or not. Bhatt et al was a prespecified secondary analysis of 
the SUMMIT study.21
The seven RCTs included in this systematic review 
were heterogeneous in nature with respect to their strat-
ification of smokers, study drug used and outcomes. 
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Stratification of smokers broadly fell into two categories: 
current smoker versus ex- smoker in four studies19 21-23 or 
heavier smoker versus lighter smoker in the remaining 
studies.18 20 24 The study drugs used were either budesonide 
or fluticasone (propionate/furoate); five studies used 
fluticasone in combination with a long- actingbeta agonist 
(LABA), either salmeterol18 22 23 or vilanterol,19–21 and the 
remaining two used fluticasone18 or budesonide alone.24 
The outcomes reported were either change in lung 
function (measured by FEV1) in four studies,
18 21 22 24 or 
yearly exacerbation rates in four studies19–21 23 (one study 
reported both). Where lung function was reported, there 
were differences in the way in which FEV1 was measured; 
Pauwels et al reported median of the post- bronchodilator 
FEV1 slope (mL/year), Bhatt et al and Snoeck- Stroband 
et al reported post- bronchodilator FEV1 and Zheng et al 
reported pre- bronchodilator FEV1. There were also minor 
differences in patient characteristics, disease severity and 
study length. All of the included studies were parallel 
group, double- blind and placebo- controlled RCTs. A 
summary of the characteristics of the trials is reported in 
table 1.
Effect on lung function
In total, 17 892 participants were included in the trials 
reporting lung function as the outcome. Bhatt et al was 
by far the largest trial with over 16 000 participants. The 
number of participants enrolled in each trial and general 
trial characteristics are shown in table 1. All four trials 
were funded by pharmaceutical companies.
There were a variety of primary outcomes reported, 
including: change in median post- bronchodilator FEV1 
over time, inflammatory cell counts and mean pre- 
bronchodilator FEV1. Follow- up was carried out at least 
every 3 months. The changes in post- bronchodilator FEV1 
in each study (except Zheng et al where pre- bronchodilator 
FEV1 is reported) are summarised in table 2. Although 
each study used the same measurement of lung func-
tion (FEV1), it was represented as either: mean (mL), 
median slope (mL/year) or interquartile median (mL). 
The pre- bronchodilator FEV1 is reported for Zheng et al 
as the authors did not stratify post- bronchodilator FEV1 
by smoking status. In addition to differences in outcome 
measure, the lack of data on number of participants in 
each smoking arm in some trials1824 means that no meta- 
analysis between the study results was possible.
The overall effect of smoking on the efficacy of ICS is 
summarised in table 2. In studies where participants were 
categorised by pack- year history,18 24 heavier smokers using 
ICS had a greater deterioration in FEV1 in comparison to 
lighter smokers using ICS. This ranged from −22 mL/year 
to −75 mL/year. However, when categorised by smoking 
status21 22 there were mixed results: current smokers’ FEV1 
ranged from −8 mL to +77 mL over the study period in 
comparison to ex- smokers or never- smokers; no statistical 
significance was reported with these results.
Effect on exacerbation rate
Three trials, Wedzicha (2016), Hinds (2015) and Pascoe 
(2019), evaluated the rate ratio of yearly COPD exac-
erbations at 52 weeks in comparison to the alternative 
treatment arm and one, Bhatt (2018), the percentage 
change in exacerbations, as indicated in (table 3).19–21 23 
Hinds et al was a post hoc cluster analysis of the Effect of 
Figure 1 Exclusion of studies identified in the search strategy. COPD, chronic obstructive pulmonary disease; ICS, inhaled 
corticosteroids; RCT, randomised controlled trial.
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Indacaterol/Glycopyrronium vs Fluticasone propionate/
Salmeterol on COPD Exacerbations (FLAME) trial where 
the participants were sorted into clusters, the cluster 
of participants included in this systematic review had 
eosinophil counts of ≤2.4% and treatment was with either 
fluticasone propionate/salmeterol (ICS/LABA) or indac-
terol/glycopyrronium (LABA/long- actingmuscarinic 
antagonist, LAMA).25 Wedzicha et al, Bhatt et al and Pascoe 
Table 2 Effect of ICS on FEV1 categorised by smoking status
Period Study Smoking status
Change in FEV1* Estimated 
effect of 
ICS on FEV1 
outcomes* P value
Estimated effect 
of smoking on 
FEV1 outcomes 
in ICS users* P valueICS Placebo
Smoking: pack- year history
0–6 months Pauwels Subjects with ≤36 
pack- year history†
30 −90 120 <0.001 −50 ‡
Subjects with >36 
pack- year history†
0 −70 70 0.57
9–36 
months
Pauwels Subjects with ≤36 
pack- year history†
−47 −71 24 0.08 22 ‡
  Subjects with >36 
pack- year history†
−67 −65 -2 0.65
0–30 
months
Snoeck- 
Stroband
Subjects with ≥42 
pack years†
−28 −63 35 0.242 −75 0.023
Subjects with <42 
pack years†
18 −92 110 0.037
Smoking: smoking status
0–6 months Zheng Never- smoked 
(n=52)
261 141 120 0.3592 – –
Ex- smokers (n=297) 177 6 171 0.0068 51 ‡
Current smokers 
(n=96)
112 −85 197 0.0022 0.337662338 ‡
0–12 
months
Bhatt Smokers (n=7678) – – 22 0.038 – –
Ex- smokers 
(n=8807)
– – 30 0.005 8 ‡
*Change in FEV1 reported. Values are in mL, except for Pauwels (1999) and Snoeck- Stroband (2015) data are expressed as mL/year.
†Number of participants in each study group not reported.
‡P value cannot be calculated from data.
FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroids.
Table 3 Effects of ICS on yearly exacerbation
Period Study
Yearly exacerbations (95% CI) Rate 
ratio* 95%ICS Alternative
0–52 
weeks
Wedzicha Current smoker (n=658 to 647) – – 0.83 0.74 to 0.92
Ex- smoker (n=998 to 1004) – – 0.92 0.83 to 1.01
0–52 
weeks
Pascoe Current smoker (n=1421 to 726) – – 0.99 0.87 to 1.12
Ex- smoker (n=2704 to 1339) – – 1.2 1.10 to 1.33
0–52 
weeks
Bhatt Current smoker (n=7678) – – 19%† 7% to 29%
Ex- smoker (n=8807) – – 36%† 27% to 43%
0–52 
weeks
Hinds >46 pack years (n=587) 1.62 (1.29 to 2.02) 1.32 (1.00 to 1.76) 0.81 0.63 to 1.06
≤46 pack years (n=891) 0.66 (0.54 to 0.81) 0.85 (0.67 to 1.08) 1.29 1.02 to 1.58
*Rate ratio of yearly exacerbations: <1 favours the alternative; >1 favours ICS, except Bhatt et al where % reduction in exacerbations versus 
placebo was reported.
†Fluticasone furoate/vilanterol versus placebo, no difference was seen for fluticasone furoate versus placebo or vilanterol versus placebo.
ICS, inhaled corticosteroids.
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et al were multicentre studies which compared fluticasone 
furoate/vilanterol (ICS/LABA) to vilanterol (LABA) or 
placebo. Each study classified smoking status differently: 
Wedzicha et al, Bhatt et al and Pascoe et al classified partic-
ipants as a current smoker or ex- smoker. Hinds et al clas-
sified them by pack- years smoked; ≤46 pack- years or >46 
pack- years thus making direct comparison between the 
results difficult. In total there were 27 460 participants.
The additional study not included in this systematic 
review, Bafadhel et al (2018), reported that smoking 
status was a predictor of response to budesonide/formo-
terol in reducing exacerbations; ex- smokers had a lower 
exacerbation ratio (vs formoterol alone) than current 
smokers.15 However, the results were stratified by eosin-
ophil count and the data could not be extracted to make 
a meaningful comparison to the other RCTs discussed 
here.
All four studies reported that current or heavier 
smokers in the ICS treatment arm were associated with 
a higher exacerbation rate than ex- smokers or lighter 
smokers. One study reported that LABA alone was less 
effective at reducing yearly exacerbation rates than ICS/
LABA if pack- year history is equal to, or less than 46 
(RR 1.29; 5% CI 1.02 to 1.58).20 But LABA alone was 
more effective if pack years >46 (RR 0.81; 95% CI 0.63 
to 1.06), however this result was not statistically signifi-
cant. Two studies reported that overall, participants who 
were current smokers in the ICS treatment arm had less 
favourable outcomes in terms of exacerbations (RR 0.83 
and 0.99; 95% CI 0.74 to 0.92 and 0.87 to 1.12) than 
ex- smokers (RR 0.92 and 1.20; 95% CI 0.83 to 1.01 and 
1.10 to 1.33).1923 The final study showed that exacerba-
tion rates were reduced with ICS/LABA versus placebo 
and that this effect was greater in ex- smokers than current 
smokers (36% vs 19%, p=0.013).21
QuALIty AssEssMEnt
Each of the seven included studies (plus the excluded 
study by Hoonhorst et al) were assessed using the 
Cochrane Collaboration’s tool for assessing the risk of 
bias (figure 2). Overall the quality of all included trials 
was high, however the main limitation was lack of infor-
mation on how the random allocation was made and how 
this was concealed. Several trials had other sources of 
bias; although randomisation was undertaken in the orig-
inal trial, the post hoc analyses reported in this systematic 
review used a subset of the original participants and there-
fore it cannot be determined if the original randomisa-
tion process holds. In addition, Hoonhorst (2014) and 
Snoeck- Stroband (2015) were powered to detect change 
in CD8 count, not lung function. Only 114 patients were 
recruited in the parent trial and it is unlikely that these 
were sufficiently powered to detect a change in lung func-
tion. Bhatt et al was a prespecified secondary analysis of 
the SUMMIT study, the results were published as a ‘letter 
to the editor’ in a shortened version of a full paper. The 
original SUMMIT trial was peer- reviewed and thus the 
results were included in this systematic review due to the 
robustness of the original data and significant number of 
participants it included.
DIsCussIOn
Heavier smokers, with a greater pack- year history, were 
less likely to benefit from ICS use in terms of lung func-
tion and yearly exacerbation rates than those who were 
lighter smokers. When categorised in terms of smoking 
status, that is, smoker or ex- smoker, the majority of partic-
ipants who were ex- smokers showed a greater increase in 
lung function and decrease in exacerbations over current 
smokers with ICS use. No definitive conclusions can be 
drawn from these data due to the lack of statistical signifi-
cance reporting for most of the results and differences in 
stratification of smoking status and measurement of lung 
function. For generalisability of results, the participants 
had a wide range of severity of COPD, however the most 
severely affected (FEV1 <30% predicted) were underrep-
resented. In addition, although changes in lung function 
and exacerbation rates were found, the magnitude of 
these changes are unlikely to be clinically significant.
In the studies that stratified participants by pack years 
smoked, dividing participants into groups of >/≤36 pack 
years or >/≤42 pack years was not justified; there were 
no documented reason why these divisions were set but 
may be because this was a post hoc analysis of the results 
and the original participants were not stratified according 
to smoking status. Furthermore, in most studies smoking 
status was self- reported by the participants at the begin-
ning of the study. There was no objective measure used 
and change in smoking status through the study was not 
accounted for.
Effect on lung function
The effect of smoking on outcomes from ICS use on lung 
function were mixed and depended on how smoking was 
defined. The decline in FEV1 found in the trials strati-
fying smoking by pack- years ranged from 22 mL/year to 
Figure 2 Quality assessment of included studies using 
Cochrane Collaboration tool for assessing risk of bias. 
Red=high risk of bias; amber=uncertain/cannot tell; 
green=low risk of bias.
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75 mL/year; implying that a greater number of pack years 
smoked resulted in a greater decline in lung function. By 
comparison, the trials that stratified by current smoking 
status found mixed results.
Of the studies that stratified by pack years smoked, the 
largest study (Pauwels et al) showed that those with >36 
pack years receiving ICS had an FEV1 decline of 50 mL/
year (median slope of FEV1 used) over those with a lighter 
smoking history at 6 months. In the longer term, Pauwels 
et al again reported a greater decline in lung function 
at 36 months in heavier smokers using ICS than lighter 
smokers, although by a reduced amount (22 mL/year). 
Snoeck- Stroband et al also found a similar result (75 mL/
year decline, p=0.023), however was a very small study and 
a high risk of bias in the way participants were selected 
from the original trial.
Of the studies that stratified by smoking status, the 
smallest study (Zheng et al) reported a decline in FEV1 
in non- smokers in comparison to ex- smokers or current 
smokers. The remaining, largest study by Bhatt et al 
accounted for over 16 000 participants and reported 
the opposite result; ex- smokers receiving ICS had less 
decline in lung function than smokers (8 mL). Although 
this result was statistically significant it is not clinically 
important. The excluded study by Hoonhorst et al also 
showed that ex- smokers had less decline in lung func-
tion at 30 months. However, the size of the study and 
the original reporting of FEV1 in litres to only two signifi-
cant figures make these results unreliable and imprecise. 
Furthermore, the lung function of smokers receiving 
placebo increased from baseline to 6 months; a result that 
is inconsistent with the wealth of literature on effects of 
smoking.
Effect on exacerbations
A clearer result was seen for effect on exacerbations; all 
studies reported a lesser decrease in yearly exacerbation 
rates when ICS was given to heavy or current smokers 
versus ex- smokers and lighter smokers; implying that ICS 
are less effective in heavier smokers. In addition, the large 
participant numbers and reporting of CIs makes us more 
certain that these are true results. However, in each set of 
results the 95% CI of the rate ratio crosses the threshold 
of one, making it possible that there is no difference 
between the comparison groups.
It was expected that smoking with ICS use would show a 
clearer impact on exacerbation rates than lung function; 
ICS are already known to have a larger impact on reducing 
rates of exacerbations than in slowing the decline of lung 
function.26 However it should be noted that in Wedzicha 
et al the effect of ICS/LABA was less than the alternative 
treatment of LAMA/LABA which may suggest ICS are of 
more limited efficacy in reducing exacerbation rates than 
other inhaled therapies, regardless of smoking status.
The outcome of this systematic review is consistent 
with the literature, indicating that steroid resistance of 
smokers to the effects of ICS may be present.10–12 27 28 
However, just as there is uncertainty in the literature as 
to whether smoking cessation reverses this resistance,13 14 
there is uncertainty here as to if smoking status effects 
outcomes with ICS. More work is needed to determine 
the pack- year quantity at which it would be expected that 
smoking would cause steroid resistance and if smoking 
cessation reduces steroid resistance. Furthermore, studies 
that report effect of smoking as a primary outcome and 
are adequately powered to detect this are needed. For 
now, clinicians should be aware that patients who are 
heavier smokers or current smokers may not respond as 
expected to ICS and that other inhaled therapies may be 
more beneficial.
COnCLusIOn
In COPD, current or heavy smokers (over 36 pack years) 
may not gain the same benefit from ICS use on lung 
function and exacerbation rates as lighter or ex- smokers 
do. This could be due to ‘steroid resistance’ caused by 
smoking, or other factors, such as difference in; severity 
of disease, co- prescribed medicines (such as bronchodi-
lators) and methodology between trials. In practice this 
means that practitioners should consider smoking status 
before prescribing ICS due to potentially reduced effi-
cacy; however further work is needed with greater patient 
numbers to determine if there is an effect of ‘steroid resis-
tance’ in current smokers.
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